1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

US FDA orders "black box" suicidality warnings and studies for Chantix and Zyban

 
• By Sue Sutter

The US FDA has ordered Pfizer and GlaxoSmithKline to add "black box" label warnings about serious neuropsychiatric effects for the smoking cessation drugs Chantix (varenicline) and Zyban (bupropion). The companies also must conduct postmarketing clinical trials to determine the incidence of serious neuropsychiatric symptoms, including depression and suicidality, in patients taking the therapies.

The US FDA has ordered Pfizer and GlaxoSmithKline to add "black box" label warnings about serious neuropsychiatric effects for the smoking cessation drugs Chantix (varenicline) and Zyban (bupropion). The companies also must conduct postmarketing clinical trials to determine the incidence of serious neuropsychiatric symptoms, including depression and suicidality, in patients taking the therapies.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

GSK Ramps Up Neuroscience Investment With ABL Brain Shuttle Deal

 
• By Andrew McConaghie

The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.

Roche’s Brain Shuttle Delivers In Alzheimer’s, Moves Ahead To Phase III

 
• By Andrew McConaghie

By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.

Axsome Plans Excessive Sleepiness Study In Depression After Phase III Failure

 
• By Alaric DeArment

The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.

Cerevance To Focus On Parkinson’s Adjunctive Therapy After Phase II Miss

 
• By Joseph Haas

After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.

More from Therapeutic Category

Rhythm Anticipates Smooth Sailing For Setmelanotide After Phase III Success

 
• By Alaric DeArment

The company plans a tiered sales approach as it targets endocrinologists for hypothalamic obesity, which is more widely diagnosed than its current indication for Bardet-Biedl syndrome.

GSK Ramps Up Neuroscience Investment With ABL Brain Shuttle Deal

 
• By Andrew McConaghie

The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.

Epsilogen Hits Antibody Acquisition Trail With TigaTx Takeover

 
• By Kevin Grogan

Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.